

Amendment and Response After Final Rejection
Serial No.: 09/248,964
Attorney Docket No.: HAR-005 (6615/8)
Page 2

E₁
wherein the second polypeptide chain comprises a fusion of, toward the N-terminus, an extracellular domain of a human MHC Class II β chain and, toward the C-terminus, a second coiled-coil dimerization domain; and

wherein the first dimerization domain and said second dimerization domain associate in solution at physiological conditions to form a heterodimer capable of selectively binding an MHC binding peptide.

E₂
114. (Amended) The MHC Class II fusion protein of claim 103 wherein the extracellular domain of the MHC Class II α chain comprises residues 5-180 of an MHC Class II α chain.

115. (Amended) The MHC Class II fusion protein of claim 103 wherein the extracellular domain of the MHC Class II α chain comprises residues 5-200 of an MHC Class II α chain.

E₃
122. (Amended) The MHC Class II fusion protein of claim 103 wherein at least one of the dimerization domains comprises a leucine zipper domain.

E₄
125. (Amended) The MHC Class II fusion protein of claim 103 further comprising a first immunoglobulin Fc domain positioned at the C-terminus of at least one of the first or second polypeptide chains.

131. (Amended) A MHC Class II-peptide complex comprising
at least one Class II MHC fusion protein comprising

a heterodimer of a first polypeptide chain and a second polypeptide chain;

E₅
wherein the first polypeptide chain comprises a fusion of, toward the N-terminus, an extracellular domain of a human MHC Class II α chain and, toward the C-terminus, a flexible molecular linker, and a first coiled-coil dimerization domain;

wherein the second polypeptide chain comprises a fusion of, toward the N-terminus, an extracellular domain of a human MHC Class II β chain and,